{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:48:18Z","timestamp":1761565698730,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jtho.2020.02.018","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T19:10:04Z","timestamp":1587755404000},"page":"689-691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Personalized Oncolytic Therapy: The Next Step Toward the Successful Clinical Application of Vaccine-Strain Measles Viruses for Cancer Therapy?"],"prefix":"10.1016","volume":"15","author":[{"given":"Tobias","family":"Peikert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2020.02.018_bib1","first-page":"26","article-title":"Observacion de un caso de enfermedad de Hodgkin, con regresion de los sintomas e infartos ganglionares, post-sarampion","volume":"8","author":"Hernandez","year":"1949","journal-title":"Arch Cubanos Cancer"},{"key":"10.1016\/j.jtho.2020.02.018_bib2","first-page":"43","article-title":"Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview","volume":"11","author":"Msaouel","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.jtho.2020.02.018_bib3","first-page":"213","article-title":"Measles virus for cancer therapy","volume":"330","author":"Russell","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jtho.2020.02.018_bib4","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/S0140-6736(17)31463-0","article-title":"Measles","volume":"390","author":"Moss","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2020.02.018_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coi.2008.01.002","article-title":"MDA5\/RIG-I and virus recognition","volume":"20","author":"Takeuchi","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jtho.2020.02.018_bib6","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.02.018_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0042-6822(02)00026-0","article-title":"Measles virus suppresses interferon-alpha signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-alpha receptor complex","volume":"306","author":"Yokota","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.jtho.2020.02.018_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/519689","article-title":"Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration","volume":"196","author":"Condack","year":"2007","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jtho.2020.02.018_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molimm.2010.10.006","article-title":"Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN-\u03b2-inducing potential","volume":"48","author":"Takaki","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jtho.2020.02.018_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s40588-016-0040-8","article-title":"Paramyxovirus glycoproteins and the membrane fusion process","volume":"3","author":"Aguilar","year":"2016","journal-title":"Curr Clin Microbiol Rep"},{"key":"10.1016\/j.jtho.2020.02.018_bib11","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/JVI.02106-12","article-title":"Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis","volume":"87","author":"Berchtold","year":"2013","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jtho.2020.02.018_bib12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jnci\/djy033","article-title":"Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy","volume":"110","author":"Kurokawa","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2020.02.018_bib13","doi-asserted-by":"crossref","first-page":"44892","DOI":"10.18632\/oncotarget.6285","article-title":"Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response","volume":"6","author":"Achard","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2020.02.018_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/1566523217666170102110502","article-title":"Modulation of the type I interferon response defines the sensitivity of human melanoma cells to oncolytic measles virus","volume":"16","author":"Allagui","year":"2017","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.jtho.2020.02.018_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261240","article-title":"Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells","volume":"6","author":"Achard","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2020.02.018_bib16","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","article-title":"Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response","volume":"68","author":"Gauvrit","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.02.018_bib17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-12-2733","article-title":"Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells","volume":"19","author":"Guillerme","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.02.018_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Res"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.02.018_bib19","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/j.jtho.2016.11.305","article-title":"OA13.07 intrapleural modified vaccine strain measles virus therapy for patients with malignant pleural mesothelioma","volume":"12","author":"Peikert","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.02.018_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/cgt.2010.10","article-title":"Oncolytic\u00a0measles viruses encoding interferon beta and\u00a0the thyroidal sodium iodide symporter gene for mesothelioma virotherapy","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jtho.2020.02.018_bib21","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtho.2020.02.018_bib22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.02.018_bib23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jtho.2019.12.128","article-title":"Frequent homozygous deletions of type I interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus","volume":"15","author":"Delaunay","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.02.018_bib24","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2020.02.018_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-11-20","article-title":"Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer","volume":"11","author":"Mader","year":"2013","journal-title":"J\u00a0Transl Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420301416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420301416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:42:11Z","timestamp":1761561731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086420301416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1556086420301416"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2020.02.018","relation":{},"ISSN":["1556-0864"],"issn-type":[{"type":"print","value":"1556-0864"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized Oncolytic Therapy: The Next Step Toward the Successful Clinical Application of Vaccine-Strain Measles Viruses for Cancer Therapy?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2020.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2019.12.128","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}